Edwards Lifesciences (EW) just delivered its latest quarterly results, and if you're holding or considering this stock, there's plenty happening to unpack. The company boosted guidance for 2025, signaling fresh confidence in its pipeline and trajectory. At the same time, Edwards announced a new $500 million accelerated share repurchase agreement, building on over $800 million already repurchased this year. While the FTC's move to block the JenaValve acquisition has nudged margin guidance, Edwards left its revenue outlook unchanged and even lifted EPS expectations slightly, sending a mixed but intriguing message to investors.